Omeros | OMER - Operating Profit


Omeros reported $-35.41M in Operating Profit for its fiscal quarter ending in September of 2024.





Operating Profit Change Date
Adma Biologics USD 50.29M 12.46M Mar/2026
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
BioMarin Pharmaceutical USD 105.6M 24.04M Jun/2026
Cytokinetics USD -179.17M 2.05M Jun/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Immunic USD -23.33M 2.67M Dec/2025
Insmed USD -101.31M 98.97M Jun/2026
Knight Therapeutics CAD 6.21M 3.27M Dec/2025
MacroGenics USD -33.44M 21.34M Mar/2026
Omeros USD -35.41M 23.75M Sep/2024
Pacira USD 9.96M 5.33M Jun/2026
Pfizer USD 667M 4.32B Jun/2026
Rockwell Medical USD 515K 1.84M Jun/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
United Therapeutics USD 330.8M 5M Jun/2026
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026